Published in J Mol Biol on June 09, 2010
Adnectins: engineered target-binding protein therapeutics. Protein Eng Des Sel (2010) 1.07
Protein-protein fusion catalyzed by sortase A. PLoS One (2011) 1.01
Natural and man-made V-gene repertoires for antibody discovery. Front Immunol (2012) 0.98
Use of (64)Cu-labeled fibronectin domain with EGFR-overexpressing tumor xenograft: molecular imaging. Radiology (2012) 0.92
Epidermal growth factor receptor downregulation by small heterodimeric binding proteins. Protein Eng Des Sel (2011) 0.91
Engineering hepatocyte growth factor fragments with high stability and activity as Met receptor agonists and antagonists. Proc Natl Acad Sci U S A (2011) 0.87
Designed hydrophilic and charge mutations of the fibronectin domain: towards tailored protein biodistribution. Protein Eng Des Sel (2012) 0.82
Co-evolution of affinity and stability of grafted amyloid-motif domain antibodies. Protein Eng Des Sel (2015) 0.80
Engineered IgG1-Fc - one fragment to bind them all. Immunol Rev (2016) 0.80
Strong Enrichment of Aromatic Residues in Binding Sites from a Charge-neutralized Hyperthermostable Sso7d Scaffold Library. J Biol Chem (2016) 0.80
Isolation and Characterization of a Monobody with a Fibronectin Domain III Scaffold That Specifically Binds EphA2. PLoS One (2015) 0.80
An enhanced approach for engineering thermally stable proteins using yeast display. Protein Eng Des Sel (2012) 0.77
A 45-Amino-Acid Scaffold Mined from the PDB for High-Affinity Ligand Engineering. Chem Biol (2015) 0.77
A Nonpolycationic Fully Proteinaceous Multiagent System for Potent Targeted Delivery of siRNA. Mol Ther Nucleic Acids (2014) 0.76
Geometry and expression enhance enrichment of functional yeast-displayed ligands via cell panning. Biotechnol Bioeng (2016) 0.75
Epitope-guided engineering of monobody binders for in vivo inhibition of Erk-2 signaling. ACS Chem Biol (2012) 0.75
Artificial affinity proteins as ligands of immunoglobulins. Biomolecules (2015) 0.75
High-Throughput Ligand Discovery Reveals a Sitewise Gradient of Diversity in Broadly Evolved Hydrophilic Fibronectin Domains. PLoS One (2015) 0.75
Efficient affinity maturation of antibody variable domains requires co-selection of compensatory mutations to maintain thermodynamic stability. Sci Rep (2017) 0.75
Clustal W and Clustal X version 2.0. Bioinformatics (2007) 126.47
Protein stability promotes evolvability. Proc Natl Acad Sci U S A (2006) 5.73
Isolating and engineering human antibodies using yeast surface display. Nat Protoc (2006) 5.02
Engineering novel binding proteins from nonimmunoglobulin domains. Nat Biotechnol (2005) 3.67
The three-dimensional structure of the tenth type III module of fibronectin: an insight into RGD-mediated interactions. Cell (1992) 3.20
High-throughput generation of synthetic antibodies from highly functional minimalist phage-displayed libraries. J Mol Biol (2007) 2.88
The fibronectin type III domain as a scaffold for novel binding proteins. J Mol Biol (1998) 2.65
Expressed murine and human CDR-H3 intervals of equal length exhibit distinct repertoires that differ in their amino acid composition and predicted range of structures. J Mol Biol (2003) 2.35
High-affinity single-domain binding proteins with a binary-code interface. Proc Natl Acad Sci U S A (2007) 2.18
Synthetic antibodies from a four-amino-acid code: a dominant role for tyrosine in antigen recognition. Proc Natl Acad Sci U S A (2004) 2.17
Yeast polypeptide fusion surface display levels predict thermal stability and soluble secretion efficiency. J Mol Biol (1999) 1.98
Semisynthetic combinatorial antibody libraries: a chemical solution to the diversity problem. Proc Natl Acad Sci U S A (1992) 1.93
Crystal structure of the tenth type III cell adhesion module of human fibronectin. J Mol Biol (1994) 1.91
Molecular recognition by a binary code. J Mol Biol (2005) 1.85
Trinucleotide phosphoramidites: ideal reagents for the synthesis of mixed oligonucleotides for random mutagenesis. Nucleic Acids Res (1994) 1.85
Picomolar affinity fibronectin domains engineered utilizing loop length diversity, recursive mutagenesis, and loop shuffling. J Mol Biol (2008) 1.64
Directed evolution of high-affinity antibody mimics using mRNA display. Chem Biol (2002) 1.57
Sortase A as a novel molecular "stapler" for sequence-specific protein conjugation. Bioconjug Chem (2007) 1.48
A dominant conformational role for amino acid diversity in minimalist protein-protein interfaces. J Mol Biol (2008) 1.45
Monobodies: antibody mimics based on the scaffold of the fibronectin type III domain. Methods Mol Biol (2007) 1.41
The intrinsic contributions of tyrosine, serine, glycine and arginine to the affinity and specificity of antibodies. J Mol Biol (2008) 1.41
Probing protein conformational changes in living cells by using designer binding proteins: application to the estrogen receptor. Proc Natl Acad Sci U S A (2002) 1.40
Design of protein function leaps by directed domain interface evolution. Proc Natl Acad Sci U S A (2008) 1.39
Synthetic therapeutic antibodies. Nat Chem Biol (2006) 1.39
Protein folding stability can determine the efficiency of escape from endoplasmic reticulum quality control. J Biol Chem (1998) 1.34
Tyrosine plays a dominant functional role in the paratope of a synthetic antibody derived from a four amino acid code. J Mol Biol (2005) 1.26
Secretion efficiency in Saccharomyces cerevisiae of bovine pancreatic trypsin inhibitor mutants lacking disulfide bonds is correlated with thermodynamic stability. Biochemistry (1998) 1.15
Antibody mimics based on human fibronectin type three domain engineered for thermostability and high-affinity binding to vascular endothelial growth factor receptor two. Protein Eng Des Sel (2005) 1.08
Molecular recognition properties of FN3 monobodies that bind the Src SH3 domain. Chem Biol (2004) 1.08
mRNA display selection of a high-affinity, modification-specific phospho-IkappaBalpha-binding fibronectin. ACS Chem Biol (2008) 1.07
Highly avid magnetic bead capture: an efficient selection method for de novo protein engineering utilizing yeast surface display. Biotechnol Prog (2009) 1.05
Directed evolution of the epidermal growth factor receptor extracellular domain for expression in yeast. Proteins (2006) 1.03
The full amino acid repertoire is superior to serine/tyrosine for selection of high affinity immunoglobulin G binders from the fibronectin scaffold. Protein Eng Des Sel (2010) 0.88
Isolating and engineering human antibodies using yeast surface display. Nat Protoc (2006) 5.02
Flow-cytometric isolation of human antibodies from a nonimmune Saccharomyces cerevisiae surface display library. Nat Biotechnol (2003) 3.34
Computational design of antibody-affinity improvement beyond in vivo maturation. Nat Biotechnol (2007) 2.92
Monovalent, reduced-size quantum dots for imaging receptors on living cells. Nat Methods (2008) 2.68
Yeast surface display for protein engineering and characterization. Curr Opin Struct Biol (2007) 2.38
A modeling analysis of the effects of molecular size and binding affinity on tumor targeting. Mol Cancer Ther (2009) 2.36
Antibody tumor penetration: transport opposed by systemic and antigen-mediated clearance. Adv Drug Deliv Rev (2008) 2.16
Polyfunctional Fc-effector profiles mediated by IgG subclass selection distinguish RV144 and VAX003 vaccines. Sci Transl Med (2014) 1.87
Theoretical analysis of antibody targeting of tumor spheroids: importance of dosage for penetration, and affinity for retention. Cancer Res (2003) 1.87
Stochastic kinetics of intracellular huntingtin aggregate formation. Nat Chem Biol (2006) 1.81
Factors determining antibody distribution in tumors. Trends Pharmacol Sci (2008) 1.80
Theoretic criteria for antibody penetration into solid tumors and micrometastases. J Nucl Med (2007) 1.69
Picomolar affinity fibronectin domains engineered utilizing loop length diversity, recursive mutagenesis, and loop shuffling. J Mol Biol (2008) 1.64
Potent inhibition of huntingtin aggregation and cytotoxicity by a disulfide bond-free single-domain intracellular antibody. Proc Natl Acad Sci U S A (2004) 1.62
Rapid tolerization of virus-activated tumor-specific CD8+ T cells in prostate tumors of TRAMP mice. Proc Natl Acad Sci U S A (2008) 1.60
Crystal structure of an HSA/FcRn complex reveals recycling by competitive mimicry of HSA ligands at a pH-dependent hydrophobic interface. Structure (2013) 1.59
Soluble IL-2RA levels in multiple sclerosis subjects and the effect of soluble IL-2RA on immune responses. J Immunol (2009) 1.55
Combination antibody treatment down-regulates epidermal growth factor receptor by inhibiting endosomal recycling. Proc Natl Acad Sci U S A (2010) 1.46
Fine epitope mapping of anti-epidermal growth factor receptor antibodies through random mutagenesis and yeast surface display. J Mol Biol (2004) 1.43
Domain-level antibody epitope mapping through yeast surface display of epidermal growth factor receptor fragments. J Immunol Methods (2004) 1.39
High-affinity lamprey VLRA and VLRB monoclonal antibodies. Proc Natl Acad Sci U S A (2009) 1.35
Effect of antigen turnover rate and expression level on antibody penetration into tumor spheroids. Mol Cancer Ther (2008) 1.32
Aglycosylated immunoglobulin G1 variants productively engage activating Fc receptors. Proc Natl Acad Sci U S A (2008) 1.31
Directed evolution of an anti-carcinoembryonic antigen scFv with a 4-day monovalent dissociation half-time at 37 degrees C. Protein Eng Des Sel (2004) 1.29
A modular IgG-scFv bispecific antibody topology. Protein Eng Des Sel (2009) 1.29
Engineering antibody affinity by yeast surface display. Methods Enzymol (2004) 1.26
A33 antigen displays persistent surface expression. Cancer Immunol Immunother (2008) 1.26
Quantitative spatiotemporal analysis of antibody fragment diffusion and endocytic consumption in tumor spheroids. Cancer Res (2008) 1.24
Kinetics of anti-carcinoembryonic antigen antibody internalization: effects of affinity, bivalency, and stability. Cancer Immunol Immunother (2008) 1.23
Selection of horseradish peroxidase variants with enhanced enantioselectivity by yeast surface display. Chem Biol (2007) 1.23
Directed evolution of a secretory leader for the improved expression of heterologous proteins and full-length antibodies in Saccharomyces cerevisiae. Biotechnol Bioeng (2009) 1.23
Identification of the epitope for the epidermal growth factor receptor-specific monoclonal antibody 806 reveals that it preferentially recognizes an untethered form of the receptor. J Biol Chem (2004) 1.23
An autoreactive antibody from an SLE/HIV-1 individual broadly neutralizes HIV-1. J Clin Invest (2014) 1.19
Structural model of the mAb 806-EGFR complex using computational docking followed by computational and experimental mutagenesis. Structure (2006) 1.18
Shuffled antibody libraries created by in vivo homologous recombination and yeast surface display. Nucleic Acids Res (2004) 1.16
High-throughput, multiplexed IgG subclassing of antigen-specific antibodies from clinical samples. J Immunol Methods (2012) 1.12
Addressing polyspecificity of antibodies selected from an in vitro yeast presentation system: a FACS-based, high-throughput selection and analytical tool. Protein Eng Des Sel (2013) 1.11
Development of a human light chain variable domain (V(L)) intracellular antibody specific for the amino terminus of huntingtin via yeast surface display. J Mol Biol (2004) 1.10
Rapid method for measuring ScFv thermal stability by yeast surface display. Biotechnol Prog (2003) 1.09
Five birds, one stone: neutralization of α-hemolysin and 4 bi-component leukocidins of Staphylococcus aureus with a single human monoclonal antibody. MAbs (2015) 1.06
Design criteria for engineering inorganic material-specific peptides. Langmuir (2005) 1.06
Highly avid magnetic bead capture: an efficient selection method for de novo protein engineering utilizing yeast surface display. Biotechnol Prog (2009) 1.05
Localized immunotherapy via liposome-anchored Anti-CD137 + IL-2 prevents lethal toxicity and elicits local and systemic antitumor immunity. Cancer Res (2013) 1.04
Highly L and D enantioselective variants of horseradish peroxidase discovered by an ultrahigh-throughput selection method. Proc Natl Acad Sci U S A (2008) 1.04
Quantitative screening of yeast surface-displayed polypeptide libraries by magnetic bead capture. Biotechnol Prog (2002) 1.03
Directed evolution of the epidermal growth factor receptor extracellular domain for expression in yeast. Proteins (2006) 1.03
Interleukin 2 (IL-2) variants engineered for increased IL-2 receptor alpha-subunit affinity exhibit increased potency arising from a cell surface ligand reservoir effect. Mol Pharmacol (2004) 1.01
Protein-protein fusion catalyzed by sortase A. PLoS One (2011) 1.01
Integrating cell-level kinetic modeling into the design of engineered protein therapeutics. Nat Biotechnol (2005) 1.01
High-affinity CD25-binding IL-2 mutants potently stimulate persistent T cell growth. Biochemistry (2005) 1.01
Improved mutants from directed evolution are biased to orthologous substitutions. Protein Eng Des Sel (2006) 1.00
Bispecific designed ankyrin repeat proteins (DARPins) targeting epidermal growth factor receptor inhibit A431 cell proliferation and receptor recycling. J Biol Chem (2011) 1.00
Triepitopic antibody fusions inhibit cetuximab-resistant BRAF and KRAS mutant tumors via EGFR signal repression. J Mol Biol (2012) 1.00
A flow cytometric assay for screening improved heterologous protein secretion in yeast. Biotechnol Prog (2006) 0.98
Divergent antibody subclass and specificity profiles but not protective HLA-B alleles are associated with variable antibody effector function among HIV-1 controllers. J Virol (2013) 0.98
Convergent potency of internalized gelonin immunotoxins across varied cell lines, antigens, and targeting moieties. J Biol Chem (2010) 0.98
Engineering an antibody with picomolar affinity to DOTA chelates of multiple radionuclides for pretargeted radioimmunotherapy and imaging. Nucl Med Biol (2010) 0.98
Directed evolution for improved secretion of cancer-testis antigen NY-ESO-1 from yeast. Protein Expr Purif (2006) 0.98
Degradation of mutated bovine pancreatic trypsin inhibitor in the yeast vacuole suggests post-endoplasmic reticulum protein quality control. J Biol Chem (2004) 0.97
Decreased Fc receptor expression on innate immune cells is associated with impaired antibody-mediated cellular phagocytic activity in chronically HIV-1 infected individuals. Virology (2011) 0.97
Independent evolution of Fc- and Fab-mediated HIV-1-specific antiviral antibody activity following acute infection. Eur J Immunol (2014) 0.96
Interleukin-2 mutants with enhanced alpha-receptor subunit binding affinity. Protein Eng (2003) 0.95
Differential requirement for CD70 and CD80/CD86 in dendritic cell-mediated activation of tumor-tolerized CD8 T cells. J Immunol (2012) 0.94
High throughput cross-interaction measures for human IgG1 antibodies correlate with clearance rates in mice. MAbs (2015) 0.94
Effect of small-molecule-binding affinity on tumor uptake in vivo: a systematic study using a pretargeted bispecific antibody. Mol Cancer Ther (2012) 0.94
Contrasting secretory processing of simultaneously expressed heterologous proteins in Saccharomyces cerevisiae. Biotechnol Bioeng (2006) 0.91
Epidermal growth factor receptor downregulation by small heterodimeric binding proteins. Protein Eng Des Sel (2011) 0.91
Antigen release kinetics in the phagosome are critical to cross-presentation efficiency. J Immunol (2008) 0.91
Rapid conformational epitope mapping of anti-gp120 antibodies with a designed mutant panel displayed on yeast. J Mol Biol (2012) 0.91
Cutting edge: delay and reversal of T cell tolerance by intratumoral injection of antigen-loaded dendritic cells in an autochthonous tumor model. J Immunol (2010) 0.90
Intestinal immunity is a determinant of clearance of poliovirus after oral vaccination. J Infect Dis (2014) 0.90
The full amino acid repertoire is superior to serine/tyrosine for selection of high affinity immunoglobulin G binders from the fibronectin scaffold. Protein Eng Des Sel (2010) 0.88
Identification of antibody glycosylation structures that predict monoclonal antibody Fc-effector function. AIDS (2014) 0.88
Biodistribution and clearance of small molecule hapten chelates for pretargeted radioimmunotherapy. Mol Imaging Biol (2011) 0.88
Peptide tags for enhanced cellular and protein adhesion to single-crystalline sapphire. Biotechnol Bioeng (2007) 0.88
A disulfide-free single-domain V(L) intrabody with blocking activity towards huntingtin reveals a novel mode of epitope recognition. J Mol Biol (2011) 0.88
Engineering fibronectin-based binding proteins by yeast surface display. Methods Enzymol (2013) 0.88
Probing the interface between biomolecules and inorganic materials using yeast surface display and genetic engineering. Acta Biomater (2005) 0.88
Protein Engineering and Selection Using Yeast Surface Display. Methods Mol Biol (2015) 0.88
Prospects for engineering HIV-specific antibodies for enhanced effector function and half-life. Curr Opin HIV AIDS (2015) 0.87
Engineered interleukin-2 antagonists for the inhibition of regulatory T cells. J Immunother (2009) 0.87
Determining the phagocytic activity of clinical antibody samples. J Vis Exp (2011) 0.87
Context-dependent mutations predominate in an engineered high-affinity single chain antibody fragment. Protein Sci (2006) 0.86
Determination of 35 cell surface antigen levels in malignant pleural effusions identifies CD24 as a marker of disseminated tumor cells. Int J Cancer (2013) 0.86
A series of anti-CEA/anti-DOTA bispecific antibody formats evaluated for pre-targeting: comparison of tumor uptake and blood clearance. Protein Eng Des Sel (2012) 0.85
Vaccine design: emerging concepts and renewed optimism. Curr Opin Biotechnol (2013) 0.84
Genetically engineered alginate lyase-PEG conjugates exhibit enhanced catalytic function and reduced immunoreactivity. PLoS One (2011) 0.83
Rolling adhesion kinematics of yeast engineered to express selectins. Biotechnol Prog (2003) 0.83
Targeted cytolysins synergistically potentiate cytoplasmic delivery of gelonin immunotoxin. Mol Cancer Ther (2013) 0.82
A multiplexed assay to detect antimicrobial peptides in biological fluids and cell secretions. J Immunol Methods (2013) 0.82
A high affinity human antibody antagonist of P-selectin mediated rolling. Biochem Biophys Res Commun (2006) 0.81
Protein engineering for therapeutics, part B. Preface. Methods Enzymol (2012) 0.81
Activation of tolerogenic dendritic cells in the tumor draining lymph nodes by CD8+ T cells engineered to express CD40 ligand. J Immunol (2010) 0.80
Separation of nonfucosylated antibodies with immobilized FcγRIII receptors. Biotechnol Prog (2013) 0.79